Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3840
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$32.18
Last synced: 2026-10-16
Market Cap
$4.32B
Change (1 day)
-6.08%
Change (1 year)
194.25%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
Market Capitalization of Definium Therapeutics, Inc.(DFTX)
Market Cap: $4.32B
As of October 2026 Definium Therapeutics, Inc. has a market cap of $4.32B. This makes Definium Therapeutics, Inc. the world's 3840th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Definium Therapeutics, Inc. from 2020 to 2026
DFTX compared with Top 5 Most Popular stocks
